Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 19/20 | 0.76 |
| ▸ | HTR1A | P08908 | 1/20 | 0.52 |
| ▸ | DRD2 | P14416 | 1/20 | 0.52 |
| ▸ | HTR2A | P28223 | 1/20 | 0.52 |
| ▸ | HTR2C | P28335 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5698353 | 0.88 | HTR6 (0.70) | HTR6HTR1ADRD2HTR2A | |
| SCHEMBL4317353 | 0.88 | HTR6 (0.65) | HTR6HTR1ADRD2HTR2A | |
| Hydrochloric Acid SCHEMBL4309981 | 0.87 | HTR6 (0.77) | HTR6HTR1ADRD2HTR2A | |
| Hydrochloric Acid SCHEMBL4316154 | 0.87 | HTR6 (0.64) | HTR6HTR1ADRD2HTR2A | |
| SCHEMBL4313475 | 0.86 | HTR6 (0.76) | HTR6HTR1ADRD2HTR2AHTR2C | |
| SCHEMBL5698325 | 0.86 | HTR6 (0.76) | HTR6HTR1ADRD2HTR2A | |
| SCHEMBL1537823 | 0.86 | HTR6 (0.76) | HTR6HTR1ADRD2HTR2A | |
| SCHEMBL1136474 | 0.86 | HTR6 (0.76) | HTR6HTR1ADRD2HTR2A | |
| SCHEMBL4306547 | 0.85 | HTR6 (0.71) | HTR6HTR1ADRD2HTR2A | |
| Hydrochloric Acid SCHEMBL4319125 | 0.85 | HTR6 (0.74) | HTR6HTR1ADRD2HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1799306-B1 | COMPOSITIONS AND METHODS FOR TREATING COGNITIVE DISORDERS | HOFFMANN LA ROCHE (CH) | 2011-02-23 | — | — | EP | claimed |
| EP-1799306-A2 | COMPOSITIONS AND METHODS FOR TREATING COGNITIVE DISORDERS | F. Hoffmann-Roche AG (CH) | 2007-06-27 | — | — | EP | claimed |
| WO-2006037482-A2 | COMPOSITIONS AND METHODS FOR TREATING COGNITIVE DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-04-13 | — | — | WO | claimed |
| US-20060069094-A1 | Compositions and methods for treating cognitive disorders | ROCHE PALO ALTO LLC | 2006-03-30 | — | — | US | claimed |
| EP-1401812-A1 | 4-PIPERAZINYLINDOLE DERIVATIVES WITH 5-HT6 RECEPTOR AFFINITY | F. HOFFMANN-LA ROCHE AG (CH) | 2004-03-31 | — | — | EP | claimed |
| US-20030045527-A1 | 4-piperazinylindole derivatives with 5-HT6 receptor affinity | SYNTEX (U.S.A.) LLC | 2003-03-06 | — | — | US | claimed |
| WO-2002102774-A1 | 4-PIPERAZINYLINDOLE DERIVATIVES WITH 5-HT6 RECEPTOR AFFINITY | F. HOFFMANN-LA ROCHE AG (CH) | 2002-12-27 | — | — | WO | claimed |
| US-20140121216-A1 | INDOLEAMINE DERIVATIVES FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISEASES | ADAMED SP. Z O.O. (PL) | 2014-05-01 | — | — | US | disclosed |
| WO-2011088836-A1 | NOVEL 4-(ARYL-4-SULFONYL)-6,6a,7,8,9,10-HEXAHYDRO-4H-4,8,10a-TRIAZA-ACEPHENANTHRYLENE AND 3-ARYLSULFONYL-6,6a,7,8,9,10-HEXAHYDRO-3H-3,8,10a-TRIAZA-CYCLOPENTA[C]FLUORENE DERIVATIVES AS SEROTONIN 5-HT6 LIGANDS | H. LUNDBECK A/S (DK) | 2011-07-28 | — | — | WO | disclosed |
| EP-2301625-A2 | Compositions and methods for treating cognitive disorders | F. Hoffmann-La Roche AG (CH) | 2011-03-30 | — | — | EP | disclosed |
| EP-1799306-B1 | COMPOSITIONS AND METHODS FOR TREATING COGNITIVE DISORDERS | HOFFMANN LA ROCHE (CH) | 2011-02-23 | — | — | EP | disclosed |
| US-7713954-B2 | Compositions and methods for treating cognitive disorders | ROCHE PALO ALTO LLC (US) | 2010-05-11 | — | — | US | disclosed |
| EP-1799306-A2 | COMPOSITIONS AND METHODS FOR TREATING COGNITIVE DISORDERS | F. Hoffmann-Roche AG (CH) | 2007-06-27 | — | — | EP | disclosed |
| EP-1401812-B1 | 4-PIPERAZINYLINDOLE DERIVATIVES WITH 5-HT6 RECEPTOR AFFINITY | HOFFMANN LA ROCHE (CH) | 2006-06-28 | — | — | EP | disclosed |
| WO-2006037482-A2 | COMPOSITIONS AND METHODS FOR TREATING COGNITIVE DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-04-13 | — | — | WO | disclosed |
| US-20060069094-A1 | Compositions and methods for treating cognitive disorders | ROCHE PALO ALTO LLC | 2006-03-30 | — | — | US | disclosed |
| US-6790848-B2 | TREATING CENTRAL NERVOUS SYSTEM OR GASTROINTESTINAL DISORDERS | SYNTEX (U.S.A.) LLC | 2004-09-14 | — | — | US | disclosed |
| EP-1401812-A1 | 4-PIPERAZINYLINDOLE DERIVATIVES WITH 5-HT6 RECEPTOR AFFINITY | F. HOFFMANN-LA ROCHE AG (CH) | 2004-03-31 | — | — | EP | disclosed |
| US-20030045527-A1 | 4-piperazinylindole derivatives with 5-HT6 receptor affinity | SYNTEX (U.S.A.) LLC | 2003-03-06 | — | — | US | disclosed |
| WO-2002102774-A1 | 4-PIPERAZINYLINDOLE DERIVATIVES WITH 5-HT6 RECEPTOR AFFINITY | F. HOFFMANN-LA ROCHE AG (CH) | 2002-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060069094-A1 | Compositions and methods for treating cognitive disorders | HTR6, HTR2A, HTR2C | HTR6 1/4885HTR1A 5/4885DRD2 88/4885 |
| US-20030045527-A1 | 4-piperazinylindole derivatives with 5-HT6 receptor affinity | HTR6, HTR5A, HTR3A | HTR6 1/4885HTR1A 6/4885DRD2 35/4885 |
| US-20140121216-A1 | INDOLEAMINE DERIVATIVES FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISEASES | TPH1, TPH2, HTR3A | HTR6 21/4885HTR1A 5/4885DRD2 105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.